Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes.

Myriad Genetics has seen a subtle but notable uptick in its fair value estimate, with analysts revising the figure from $7.95 to $8.29. This slight increase comes as experts reassess the company's ...

Earlier this year, researchers at Children's Hospital of Philadelphia and Penn created a first-of-its-kind drug customized to ...

Radboudumc and Maastricht UMC+ are the first hospitals in the world to use a new genetic test to diagnose rare diseases on a ...

Tempus AI shows strong Q3 growth with 85% higher sales, robust oncology and data licensing momentum, and attractive 7.5x ’26 ...

The Ontario Hereditary Cancer Research Network's (OHCRN) participant portal is now open and Ontarians at risk of hereditary cancers are invited to register.

The Oakland County school is one of 20 schools nationwide performing genetic research through a partnership with Stanford ...

Scientists Just Discovered a Quantum Physics Loophole—And It Could Finally Unlock Interstellar Travel Predator who kidnapped, ...

Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...

UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM ESTCompany ParticipantsBrandon Perthuis - Chief ...

Maximizing a crop’s output may begin with high-yielding, disease-resistant varieties, but the team at FP Genetics believes ...